Investors

You heard it here first.

 
 
 

Our news

Bringing you the latest!

Investors

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

Corporate - Investors

17 December 2020

MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations

Investors

9 December 2020

MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin

Corporate - Investors

6 April 2020

 
 

CONTACT

  • This field is for validation purposes and should be left unchanged.